{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"ORR is defined as participants who experience a partial response, very good partial response, complete response, or stringent complete response per International Myeloma Working Group Criteria (IMWG) 2016 criteria. Complete Response is defined as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow aspirates. Stringent Complete Response is defined as complete response as noted previously plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry. Partial Response is ≥50% reduction of serum M-protein plus reduction in 24 hour urinary M-protein by ≥90% or to \\<200 mg per 24 h. Very Good Partial Response is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hr.","groups":[{"description":"Selinexor\n\n• Given orally at a dose of 60 mg on days 1, 8, and 15 of a 28-day cycle.\n\nDexamethasone\n\n* Given orally at a dose of 40 mg on days 1, 8, 15 and 22 of a 28-day cycle.\n* Subjects will receive a prescription for dexamethasone 4 mg tablets (generic).\n\nClarithromycin\n\n* Given orally at a dose of 500 mg twice a day on days 1-28 of a 28-day cycle.\n* Subjects will receive a prescription for clarithromycin 250 or 500 mg tablets (generic) for oral administration.\n\nPomalidomide\n\n* Given orally at a dose of 4 mg daily on days 1-21 of a 28-day cycle.\n* Subjects will receive a 21-day supply of pomalidomide 1, 2, 3, or 4 mg capsules for oral administration for each treatment cycle.\n\nSelinexor: Given as 60 mg oral capsule\n\nClarithromycin: Given as 500 mg oral capsule\n\nPomalidomide: Given as 4 mg oral capsule\n\nDexamethasone: Given as 40 mg oral capsule","id":"OG000","title":"Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Until disease progression; the maximum time any participant was followed for ORR was 287 days","title":"Percentage of Participants With Overall Response Rate of Partial Response or Better","type":"PRIMARY","unitOfMeasure":"Participants"}